Prostate cancer: open trials in Austria

• NCT06136624

  Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

  Trial Treatment · Phase 3 · Merck Sharp & Dohme LLC

  Medical University of Graz, Graz · Ordensklinikum Linz GmbH, Linz · Klinikum Wels-Grieskirchen GmbH, Wels

  Registry updated 2026-11-05

• NCT06925737

  A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

  Trial Treatment · Phase 3 · Merck Sharp & Dohme LLC

  Ordensklinikum Linz GmbH, Linz · SCRI CCCIT Ges.m.b.H., Salzburg · Klinikum Wels-Grieskirchen GmbH, Wels

  Registry updated 2026-10-30

• NCT07262619

  EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors

  Trial Treatment · Phase 1/2 · Eikon Therapeutics

  Ordensklinikum Linz Elisabethinen, Linz

  Registry updated 2026-10-30

• NCT05939414

  An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.

  Trial Treatment · Phase 3 · Novartis Pharmaceuticals

  Ordensklinikum Linz GmbH, Linz · Medical University of Vienna, Vienna

  Registry updated 2026-10-21

• NCT07213674

  A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

  Trial Treatment · Phase 3 · Amgen

  Medizinische Universitaet Innsbruck, Innsbruck · Ordensklinikum Linz Elisabethinen, Linz · Universitaetsklinikum Sankt Poelten, Sankt Pölten · Universitaetsklinikum Allgemeines Krankenhaus Wien, Vienna · Krankenhaus Der Barmherzigen Brueder Wien, Vienna

  Registry updated 2026-10-20

• NCT07611110

  AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

  Trial Treatment · Phase 3 · AstraZeneca

  Linz · Salzburg · Vienna

  Registry updated 2026-10-19

• NCT07711002

  Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)

  Trial Treatment · Phase 3 · AstraZeneca

  Medical University of Graz, Graz · Ordensklinikum Linz GmbH, Linz · Gemeinnuetzige Salzburger Landeskliniken Betriebsgesellschaft mbH, Salzburg · Medical University of Vienna, Vienna

  Registry updated 2026-10-15

• NCT06952803

  A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

  Trial Treatment · Phase 3 · AstraZeneca

  Medical University of Graz, Graz · Medizinische Universitaet Innsbruck, Innsbruck · Ordensklinikum Linz GmbH, Linz · Krankenhaus Der Barmherzigen Brueder Wien, Vienna · Medical University of Vienna, Vienna

  Registry updated 2026-10-14

• NCT05176483

  Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

  Trial Treatment · Phase 1 · Exelixis

  University Hospital Graz, Graz · Krankenhaus Der Barmherzigen Brueder Wien, Vienna · Medical University of Vienna, Vienna

  Registry updated 2026-10-01

• 2025-520555-89-00

  Phase 3 Study of Xaluritamig Plus Abiraterone vs Investigator's Choice in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

  Trial Treatment · Phase 3 · Amgen Inc.

  Medical University of Graz, Graz · Medizinische Universitaet Innsbruck, Innsbruck · Ordensklinikum Linz GmbH, Linz · Noe LGA Gesundheit Region Mitte GmbH, St. Poelten · Medical University of Vienna, Vienna · Krankenhaus Der Barmherzigen Brueder Wien, Vienna

  Registry updated 2026-09-17

• NCT04641247

  A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study

  Trial Treatment · Phase 2 · GlaxoSmithKline

  Medical University of Graz, Graz · Medical University of Vienna, Vienna

  Registry updated 2026-06-24

• NCT06579911

  Combining High-frequency Micro-ultrasound and Multiparametric MRI Target Biopsy for Detecting Prostate Cancer

  Trial Treatment · Salzburger Landeskliniken

  Uniklinikum Salzburg, Department for Urology and Andrology, Salzburg

  Registry updated 2026-06-09

• NCT05803941

  Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer

  Trial Treatment · Phase 4 · Novartis Pharmaceuticals

  Ordensklinikum Linz GmbH, Linz · Allgemeines Krankenhaus Der Stadt Wien Universitatskliniken, Vienna

  Registry updated 2026-06-04

• NCT02971358

  Safety and Early Efficacy of Radical Prostatectomy for Newly Diagnosed Very High Risk Locally Advanced and Oligometastatic Prostate Cancer

  Trial Treatment · Medical University of Vienna

  Medical University of Vienna, Vienna

  Registry updated 2025-05-14

• NCT06259123

  Neoadjuvant PSMA-RLT in Oligometastatic PCa

  Trial Treatment · Phase 2 · Medical University of Vienna

  Medical University of Vienna, Vienna

  Registry updated 2024-02-15

• NCT06220188

  PSMA-RLT in Biochemically Recurrent PCa

  Trial Treatment · Phase 2 · Medical University of Vienna

  Medical University of Vienna, Vienna

  Registry updated 2024-02-13

All Prostate cancer trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error